A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1−SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Trial Profile

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1−SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms IMmotion010
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 1 Feb 2021 to 20 Apr 2024.
    • 14 Sep 2017 Planned primary completion date changed from 1 Feb 2021 to 24 May 2022.
    • 12 Sep 2017 Planned End Date changed from 2 Sep 2024 to 1 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top